Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  health care costs
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

An analysis of potential costs of adverse events based on Drug Programs in Poland. Pulmonology focus

100%
Szkultecka-Debek M., Drozd M., Jahnz-Rozyk K., Kiepurska N., Mazurek J., Janowska A., Paprzycki P., Adamczyk-Korbel M., Paluchowska B., Drozd K.
Current Issues in Pharmacy and Medical Sciences
|
2014
|
vol. 27
|
issue 1
32-36
EN
The project was performed within the Polish Society for Pharmacoeconomics (PTFE). The objective was to estimate the potential costs of treatment of side effects, which theoretically may occur as a result of treatment of selected diseases. We analyzed the Drug Programs financed by National Health Fund in Poland in 2012 and for the first analysis we selected those Programs where the same medicinal products were used. We based the adverse events selection on the Summary of Product Characteristics of the chosen products. We extracted all the potential adverse events defined as frequent and very frequent, grouping them according to therapeutic areas. This paper is related to the results in the pulmonology area. The events described as very common had an incidence of ≥ 1/10, and the common ones ≥ 1/100, <1/10. In order to identify the resources used, we performed a survey with the engagement of clinical experts. On the basis of the collected data we allocated direct costs incurred by the public payer. We used the costs valid in December 2013. The paper presents the estimated costs of treatment of side effects related to the pulmonology disease area. Taking into account the costs incurred by the NHF and the patient separately e calculated the total spending and the percentage of each component cost in detail. The treatment of adverse drug reactions generates a significant cost incurred by both the public payer and the patient.
2
Publication available in full text mode
Content available

Emergency Medicine: a specialty that deserves “re-branding,” because it enables large financial savings!

100%
Gaddis G. M.
|
EN
Emergency departments are costly to maintain. They remain open every hour of the year to provide care for those who need it, when they need it. Therefore, emergency departments are a crucial resource for any modern society, and no sensible person would want to close them, despite their cost. However, the view held by many, that the care provided in an emergency department is excessively costly, is just plain wrong. When our doctors’ and our specialty’s performance is viewed objectively, it becomes clear that emergency physicians have become crucial agents of cost savings. Therefore, EPs have earned the right to proudly “re-brand” themselves not as high-cost care providers, but as indispensable, money-savers in any nation’s health care enterprise. If you don’t believe that, continue reading this commentary.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.